These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
65. MR contrast agents in acute experimental cerebral ischemia: potential adverse impacts on neurologic outcome and infarction size. Doerfler A; Engelhorn T; Heiland S; Knauth M; Wanke I; Forsting M J Magn Reson Imaging; 2000 Apr; 11(4):418-24. PubMed ID: 10767071 [TBL] [Abstract][Full Text] [Related]
66. A functionalized superparamagnetic iron oxide colloid as a receptor directed MR contrast agent. Josephson L; Groman EV; Menz E; Lewis JM; Bengele H Magn Reson Imaging; 1990; 8(5):637-46. PubMed ID: 1707120 [TBL] [Abstract][Full Text] [Related]
67. State of the art in diagnostic liver imaging. Lamprecht A; Wagner B Eur Radiol; 2004 Jan; 14 Suppl 1():C2-3. PubMed ID: 15113057 [No Abstract] [Full Text] [Related]
68. Phase I clinical evaluation of citrate-coated monocrystalline very small superparamagnetic iron oxide particles as a new contrast medium for magnetic resonance imaging. Taupitz M; Wagner S; Schnorr J; Kravec I; Pilgrimm H; Bergmann-Fritsch H; Hamm B Invest Radiol; 2004 Jul; 39(7):394-405. PubMed ID: 15194910 [TBL] [Abstract][Full Text] [Related]
69. Experience with Resovist in gastroenterologic radiology and intervention. Vogl TJ; Schwarz W; Marquart F; Parmentier S; Götz B; Thalhammer A; Hammerstingl R Eur Radiol; 2004 Jan; 14 Suppl 1():C7-9. PubMed ID: 15113060 [No Abstract] [Full Text] [Related]
70. Preliminary clinical experience with AMI 227. McLachlan SJ; Morris M; Lucas MA; Baum LM Acad Radiol; 1996 Aug; 3 Suppl 2():S295-6. PubMed ID: 8796584 [No Abstract] [Full Text] [Related]
71. Evaluation of Ferucarbotran (Resovist) as a photoacoustic contrast agent / Evaluation von Ferucarbotran (Resovist) als photoakustisches Kontrastmittel. Mienkina MP; Friedrich CS; Hensel K; Gerhardt NC; Hofmann MR; Schmitz G Biomed Tech (Berl); 2009 Apr; 54(2):83-8. PubMed ID: 19335122 [TBL] [Abstract][Full Text] [Related]
72. Questionnaire survey of acute and delayed adverse reactions to ferumoxides. Kurata T; Tanimoto A; Shinmoto H; Yuasa Y; Kuribayashi S Radiat Med; 2005 Nov; 23(7):468-73. PubMed ID: 16485536 [TBL] [Abstract][Full Text] [Related]
73. Murine atherosclerotic plaque imaging with the USPIO Ferumoxtran-10. Klug G; Kampf T; Ziener C; Parczyk M; Bauer E; Herold V; Rommel E; Jakob PM; Bauer WR Front Biosci (Landmark Ed); 2009 Jan; 14(7):2546-52. PubMed ID: 19273218 [TBL] [Abstract][Full Text] [Related]
75. Safety and tolerability of ultrasmall superparamagnetic iron oxide contrast agent: comprehensive analysis of a clinical development program. Bernd H; De Kerviler E; Gaillard S; Bonnemain B Invest Radiol; 2009 Jun; 44(6):336-42. PubMed ID: 19661843 [TBL] [Abstract][Full Text] [Related]
76. Magnetic particle imaging: kinetics of the intravascular signal in vivo. Haegele J; Duschka RL; Graeser M; Schaecke C; Panagiotopoulos N; Lüdtke-Buzug K; Buzug TM; Barkhausen J; Vogt FM Int J Nanomedicine; 2014; 9():4203-9. PubMed ID: 25214784 [TBL] [Abstract][Full Text] [Related]
77. Preclinical assessment of hepatocyte-targeted MR contrast agents in stable human liver cell cultures. Reimer P; Bader A; Weissleder R J Magn Reson Imaging; 1998; 8(3):687-9. PubMed ID: 9626887 [TBL] [Abstract][Full Text] [Related]
78. Initial assessment of magnetoferritin biokinetics and proton relaxation enhancement in rats. Bulte JW; Douglas T; Mann S; Vymazal J; Laughlin PG; Frank JA Acad Radiol; 1995 Oct; 2(10):871-8. PubMed ID: 9419653 [TBL] [Abstract][Full Text] [Related]
79. Role of Iron Oxide (Fe Pourmadadi M; Rahmani E; Shamsabadipour A; Mahtabian S; Ahmadi M; Rahdar A; Díez-Pascual AM Nanomaterials (Basel); 2022 Nov; 12(21):. PubMed ID: 36364649 [TBL] [Abstract][Full Text] [Related]
80. Ten Things You Might Not Know about Iron Oxide Nanoparticles. Daldrup-Link HE Radiology; 2017 Sep; 284(3):616-629. PubMed ID: 28825888 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]